Hemangiosarcoma
Methodology & AI Transparency ⓘ
Hemangiosarcoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Hemangiosarcoma (ICD-10-CM C49.9), Cancer, Oncology & Supportive Care protocols prioritize immunohistochemistry [Hemangiosarcoma C49.9] paired with baseline and interval Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) assessment.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C49.9 for Hemangiosarcoma clinical workups.
- 3 Typical cash cost range: Primary evaluation for Hemangiosarcoma incorporates immunohistochemistry [Hemangiosarcoma C49.9] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Hemangiosarcoma: Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) (Guideline-concordant surveillance (C49.9)) and Complete Blood Count in Hemangiosarcoma (C49.9: (ANC, Hemoglobin, Platelets)).
Ask our AI Specialists anything about Hemangiosarcoma
What Is Hemangiosarcoma?
For patients presenting with Hemangiosarcoma (ICD-10-CM C49.9), Cancer, Oncology & Supportive Care protocols prioritize immunohistochemistry [Hemangiosarcoma C49.9] paired with baseline and interval Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in cancer & oncology, Hemangiosarcoma (C49.9) involves immune-checkpoint evasion [Hemangiosarcoma C49.9]. progression correlates with shifts in Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) (Guideline-concordant surveillance (C49.9)).
Common Symptoms & Clinical Signs
- • Presentation of Hemangiosarcoma (C49.9): unintended weight loss [Hemangiosarcoma C49.9]
- • Secondary Hemangiosarcoma clinical sign: unexplained bleeding, chronic in Hemangiosarcoma (C49.9: hoarseness/cough, or progressive)
- • Symptom flares in Hemangiosarcoma correlating with Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) deviation outside Guideline-concordant surveillance (C49.9)
- • Functional cancer & oncology impact requiring immunohistochemistry [Hemangiosarcoma C49.9] evaluation (C49.9)
Hemangiosarcoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C49.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Pathology / Molecular in Hemangiosarcoma (C49.9: Genomic Staging) | Guideline-concordant surveillance (C49.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Hemangiosarcoma (C49.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C49.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Hemangiosarcoma (C49.9: Organ Function Panel) | Preserved renal/hepatic clearance (C49.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hemangiosarcoma
Treatment selection for Hemangiosarcoma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hemangiosarcoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Body-mass index on treatment and outcome in locally advanced rectal cancer: A: What a 1,236-Participant Study Found In our study, underweight and overweight correlated with inferior DFS, underweight experienced more organ toxicity and obesity was associated with an increased risk of abdominoperineal resection and poorer overall. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2021-11-15 • Phase III Randomized Trial | N = 1,236 | 90/100 | PMID 34619239 ↗ |
| Can This Approach Help? Inside the Latest Research on Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance. Blood cancer journal • 2025-12-04 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41345095 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine and Exposure-Response Analyses of Ibrutinib 560 mg, combined with BR, consistently improves PFS across the ibrutinib exposure range evaluated. CPT: pharmacometrics & systems pharmacology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40613748 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as Camrelizumab plus rivoceranib was more cost effective than sorafenib as first-line therapy for unresectable HCC in the Chinese setting. Clinical drug investigation • 2024-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38300386 ↗ |
| Can This Approach Help? Inside the Latest Research on Concentration-QTcF analysis of quizartinib in patients with newly diagnosed In newly diagnosed AML patients, ΔQTcF increased non-linearly with increasing quizartinib concentrations. Clinical and translational science • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39533519 ↗ |
Hemangiosarcoma Patient Community & “People Like Me” Threads
Filter Hemangiosarcoma community threads and patient logs by age, biological sex, dosage, and treatment duration.